Baseline interleukin‐10 levels as a predictive biomarker for achieving clinical response with abatacept in disease‐modifying antirheumatic drug‐naive and anticitrullinated protein antibody‐positive patients with early rheumatoid arthritis

Treatment with abatacept+MTX resulted in significantly greater reduction of biomarkers relevant to RA, and high baseline IL-10 levels predicted better treatment response with abatacept+MTX versus placebo+MTX across clinical outcomes. Findings suggest a well-suited mechanism of action for abatacept+MTX in patients with early RA and high baseline IL-10 levels.